PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28032735-0	2016	Combined Treatment with Stattic and Docetaxel Alters the Bax/Bcl-2 Gene Expression Ratio in Human Prostate Cancer Cells Docetaxel, recognized as a stabilizing microtubule agent, is frequently administrated as a first line treatment forprostate cancers.	stattic	24-31	BCL2 apoptosis regulator	Homo sapiens	61-66